Inhibikase Therapeutics (IKT) financial statements
Net income was -$48M.
Free cash flow was -$28M.
The diluted share count rose 7082% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Inhibikase Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $698,468 | $3M | $123,440 | $260,501 | $0 | — |
| Research and development | $893,802 | $11M | $12M | $14M | $17M | $30M |
| Selling, general and admin | $3M | $7M | $6M | $7M | $11M | $24M |
| Operating income | -$3M | -$15M | -$18M | -$20M | -$29M | -$52M |
| Interest expense | $29,402 | $19,923 | — | — | — | — |
| Pre-tax income | — | — | — | — | -$27,520 | -$48,259 |
| Income tax | — | — | — | — | $0 | $0 |
| Net income | -$3M | -$15M | -$18M | -$19M | -$28M | -$48M |
| EPS (diluted) | -$2.10 | -$4.86 | -$4.28 | -$3.16 | -$1.16 | -$0.49 |
| Diluted shares | 1M | 3M | 4M | 6M | 24M | 98M |
| Operating margin | -403.5% | -476.2% | -14686.2% | -7712.0% | — | — |
| Net margin | -407.7% | -476.9% | -14625.9% | -7304.7% | — | — |
Balance sheet
Fiscal years, from Inhibikase Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $14M | $41M | $23M | $13M | $98M | $179M |
| Total current assets | $15M | $42M | $24M | $14M | $98M | $180M |
| Property, plant and equipment | — | $0 | $236,532 | $73,372 | $47,100 | $0 |
| Total assets | $15M | $42M | $25M | $15M | $99M | $181M |
| Total current liabilities | $5M | $4M | $4M | $3M | $4M | $8M |
| Total liabilities | $5M | $4M | $4M | $4M | $4M | $8M |
| Shareholders' equity | $10M | $38M | $21M | $11M | $95M | $173M |
| Net debt | -$14M | -$41M | -$7M | -$9M | -$56M | -$139M |
Cash flow
Fiscal years, from Inhibikase Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1M | -$14M | -$17M | -$18M | -$19M | -$28M |
| Capital spending | — | $0 | $243,255 | $14,238 | $0 | $13,399 |
| Free cash flow | — | -$14M | -$18M | -$18M | -$19M | -$28M |
| Stock-based compensation | $573,695 | $2M | $458,147 | $500,148 | $8M | $15M |
| Free cash flow margin | — | -461.1% | -14253.4% | -6947.9% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IKT.
Open IKT in InvestinglyQuestions
How much free cash flow does Inhibikase Therapeutics generate?
-$28M in fiscal 2025 (operating cash flow minus capital spending).
From Inhibikase Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.